01046-A: The Relevance of Ezrin in the Metastatic Progression of Canine Osteosarcoma
Grant Status: Closed
Project SummaryTo-date our work to understand ezrin�s role in cancer spread has been limited to mouse and human OS. In order that pet dogs benefit from the development of novel ezrin related therapies and that clinical trials that include pet dogs can be integrated into the development of new therapies, it is necessary to confirm our ezrin findings in canine OS cells. We have made substantial progress in developing and characterizing canine osteosarcoma cells that we can include in the study of this aggressive and metastatic bone tumor. The study of osteosarcoma biology in canine using these cells can now be aligned with current efforts in our laboratory using murine and human osteosarcoma cells. The collective outcome of this work will be to improve outcomes for canine and pediatric OS patients. We have previously studied the role of ezrin, a cytoskeleton linker protein, in mouse OS cell lines. These studies have led us to believe that the contribution provided by ezrin to the metastatic phenotype may be blocked through the use of PKC inhibitors. Using our newly characterized OS cell lines we have similarly connected ezrin and PKC signaling in canine OS. These data begin to pave the way towards therapeutic studies against osteosarcoma using clinically available PKC inhibitors.
Help Future Generations of Dogs
Participate in canine health research by providing samples or by enrolling in a clinical trial. Samples are needed from healthy dogs and dogs affected by specific diseases.